GB9511935D0 - Novel compound - Google Patents

Novel compound

Info

Publication number
GB9511935D0
GB9511935D0 GBGB9511935.0A GB9511935A GB9511935D0 GB 9511935 D0 GB9511935 D0 GB 9511935D0 GB 9511935 A GB9511935 A GB 9511935A GB 9511935 D0 GB9511935 D0 GB 9511935D0
Authority
GB
United Kingdom
Prior art keywords
novel compound
novel
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9511935.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9511935.0A priority Critical patent/GB9511935D0/en
Publication of GB9511935D0 publication Critical patent/GB9511935D0/en
Priority to EP96917584A priority patent/EP0832219A2/en
Priority to JP9502784A priority patent/JPH11507547A/en
Priority to CA002224646A priority patent/CA2224646A1/en
Priority to PCT/GB1996/001388 priority patent/WO1997000319A2/en
Priority to AU60110/96A priority patent/AU6011096A/en
Priority to US09/859,361 priority patent/US20020058311A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
GBGB9511935.0A 1995-06-13 1995-06-13 Novel compound Pending GB9511935D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB9511935.0A GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound
EP96917584A EP0832219A2 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
JP9502784A JPH11507547A (en) 1995-06-13 1996-06-11 Chimeric leptin fused with immunoglobulin domain and uses thereof
CA002224646A CA2224646A1 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
PCT/GB1996/001388 WO1997000319A2 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
AU60110/96A AU6011096A (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
US09/859,361 US20020058311A1 (en) 1995-06-13 2001-05-17 Chimeric leptin fused to immunoglobulin domain and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9511935.0A GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound

Publications (1)

Publication Number Publication Date
GB9511935D0 true GB9511935D0 (en) 1995-08-09

Family

ID=10775951

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9511935.0A Pending GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound

Country Status (6)

Country Link
EP (1) EP0832219A2 (en)
JP (1) JPH11507547A (en)
AU (1) AU6011096A (en)
CA (1) CA2224646A1 (en)
GB (1) GB9511935D0 (en)
WO (1) WO1997000319A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
IL124442A0 (en) * 1995-11-22 1998-12-06 Amgen Inc Methods of increasing lean tissue mass using ob protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE69632546T2 (en) * 1995-12-27 2005-06-30 Genentech, Inc., South San Francisco OB PROTEIN DERIVATIVES WITH EXTENDED HALF TIME
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
CZ298203B6 (en) * 1996-12-20 2007-07-18 Amgen Inc. OB fusion protein, nucleic acid sequence, vector, host cell, method of preparing protein, use thereof in the preparation of medicament, and pharmaceutical composition
WO1998036763A1 (en) * 1997-02-25 1998-08-27 Eli Lilly And Company Treatment of infertility with leptin receptor ligands
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
CN1202862C (en) * 1997-04-17 2005-05-25 安姆根有限公司 Compsns. comprising comjugates of stable, active, human OB protein with antibody Fc chain and methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
WO1999002709A1 (en) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
PL199659B1 (en) * 1998-02-25 2008-10-31 Merck Patent Gmbh Antibody-based fusion protein featured by prolonged residence in a cireculatory system and method of prolonging its residence time in a circulatory system
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
JP2002534962A (en) * 1999-01-07 2002-10-22 レキシジェン ファーマシューティカルズ コーポレイション Expression and transport of anti-obesity proteins as Fc fusion proteins
MXPA01011264A (en) * 1999-05-07 2002-07-02 Genentech Inc Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same.
WO2001025428A1 (en) * 1999-10-01 2001-04-12 Eli Lilly And Company A novel human leptin homolog
AU4314801A (en) * 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
ATE300611T1 (en) 2000-05-22 2005-08-15 Vlaams Interuniv Inst Biotech RECEPTOR-BASED SCREENING METHODS FOR PROTEIN INTERACTIONS
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
MXPA03007323A (en) * 2001-02-19 2003-12-12 Merck Patent Gmbh Artificial proteins with reduced immunogenicity.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
JP2007505643A (en) * 2003-06-12 2007-03-15 イーライ リリー アンド カンパニー Fusion protein
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
KR100725315B1 (en) 2003-11-13 2007-06-07 한미약품 주식회사 Protein complex using an immunoglobulin fragment and method for the preparation thereof
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EA011859B9 (en) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Compounds for targeted preparation delivery to tissue or targeted organ
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
DK1831252T3 (en) * 2004-12-22 2009-10-05 Lilly Co Eli GLP-1 analog fusion protein formulations
EP2441838A3 (en) * 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
EP2421896A1 (en) 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59109269D1 (en) * 1990-06-28 2005-12-15 Hoechst Ag Fusion proteins with immunoglobulin components, their preparation and use
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
CA2218529A1 (en) * 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity

Also Published As

Publication number Publication date
EP0832219A2 (en) 1998-04-01
CA2224646A1 (en) 1997-01-03
AU6011096A (en) 1997-01-15
WO1997000319A2 (en) 1997-01-03
JPH11507547A (en) 1999-07-06
WO1997000319A3 (en) 1997-04-10

Similar Documents

Publication Publication Date Title
GB9511935D0 (en) Novel compound
AP9701021A0 (en) Novel compounds
EP0802908A4 (en) Novel compounds
GB9507203D0 (en) Novel compounds
GB9509164D0 (en) Novel compounds
GB9503717D0 (en) Novel compounds
GB9518417D0 (en) Novel compound
GB9511934D0 (en) Novel compound
GB9511936D0 (en) Novel compound
GB9511933D0 (en) Novel compound
GB9503112D0 (en) Novel compound
GB9502297D0 (en) Novel compound
GB9501157D0 (en) Novel compound
GB9500400D0 (en) Novel compound
GB9500399D0 (en) Novel compound
GB9511937D0 (en) Novel compound
GB9526538D0 (en) Novel compound
GB9500447D0 (en) Compound
GB9503173D0 (en) Novel compounds
GB9504400D0 (en) Novel compounds
GB9510185D0 (en) Novel compounds
GB9502051D0 (en) Novel compounds
GB9502052D0 (en) Novel compounds
GB9503172D0 (en) Novel compounds
GB9500262D0 (en) Novel compounds